Newsletter | October 1, 2019

10.01.19 -- Newly Discovered Target Overcomes Drug Resistance In Lethal Blood Cancer

 
Industry Insights
Manufacturing Process Scale-Up For Phase III
White Paper | By Sanjay Konagurthu, Ph.D., and John W. Burke, Thermo Fisher Scientific

The reality is that several manufacturability problems could be brewing that will rain down during Phase III and cause costly delays, no matter how skilled the product and process may be.

Biomarkers For The Brain
Article | By Christi Bird, Principal Consultant, Transformational Health, Frost & Sullivan

Frost & Sullivan recently invited academic and industry leaders in neuroscience research to participate in a unique thought leadership forum, our Virtual Think Tank series, titled Biomarkers for the Brain. This forum brought together leading minds involved in the study of biomarkers of central nervous system (CNS) diseases and disorders. 

Quantitating Binding Similarities In IgG Fc Receptor Analysis
Application Note | GE Healthcare Life Sciences

Critical quality attributes (CQA) are fundamental to regulatory compliance and in drug development and manufacturing. Find out how surface plasmon resonance has been applied for protein characterization of antibody effector function.

A Novel Cell-Based Screening Assay For Cholesterol Biosynthetic Pathway Inhibition Using The RapidFire HTMS Platform
White Paper | GVK Biosciences

A client was exploring the possibility of re-purposing an internal collection of antifungal CYP51A1 inhibitors for targeting cancers. GVK BIO was commissioned to enable the such project. Learn how a CYP51A1 inhibitor screening assay using the RapidFire HTMS method was deemed to be optimized, and screening of client compounds was enabled with an acceptable throughput and in a cost-effective manner. 

Most Popular News
Solutions
Quality Solution Brief
Dassault Systemes Americas
Life Science Leader Magazine
 

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.